Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash from Operations (2016 - 2025)

Neuroone Medical Technologies' Cash from Operations history spans 14 years, with the latest figure at 3115835.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 1597.64% year-over-year to 3115835.0; the TTM value through Dec 2025 reached 6161156.0, up 11.91%, while the annual FY2025 figure was 2837272.0, 74.23% up from the prior year.
  • Cash from Operations reached 3115835.0 in Q4 2025 per NMTC's latest filing, down from 1525672.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1017817.0 in Q3 2022 to a low of 3809391.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 2203497.45, with a median of 2508247.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: soared 150.16% in 2022, then tumbled 1597.64% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 2679136.0 in 2021, then tumbled by 30.35% to 3492253.0 in 2022, then dropped by 9.08% to 3809391.0 in 2023, then skyrocketed by 105.46% to 208049.0 in 2024, then tumbled by 1597.64% to 3115835.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Cash from Operations are 3115835.0 (Q4 2025), 1525672.0 (Q3 2025), and 1463505.0 (Q2 2025).